In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Too Early For Tools?

Executive Summary

Advances in high-throughput screening and metagenomic data analysis have already helped uncover the microbiome’s potential as a source of new therapeutic approaches. But more new tools will be needed to further decipher it.

AvidBiotics Corp.’s Avidocin proteins are engineered to target a single bacterium strain without collateral damage. The proteins – tweaked versions of R-type bacteriocins, or naturally occurring defensive bacterial proteins – zero in in unique surface molecules of the bacterial targets, without hitting or harming off-target bacteria. This “sniper rifle” approa

ch is potentially a very useful microbiome research tool. But the company has struggled to monetize it. That’s in part because the obvious immediate application, in narrow spectrum antibiotics, isn’t commercially attractive to most Big Pharma. It’s also because of the relative immaturity of the microbiome field. “It’s still early in the [microbiome] game,” explains chairman and CEO David Martin. In most companies (Johnson & Johnson and perhaps Novartis AG excepted) “there’s no microbiome silo,” only therapy area groups. Those in immunology, inflammatory, and/or metabolic diseases tend to be the most excited, yet many of those are focused on adding bacteria (along the lines of FT or probiotics), while “we’re talking about selective subtraction.”

AvidBiotics’ project to find an effective prophylactic for C. difficile, to prevent colonization to begin with, and/or avoid relapse, is also a hard sell. “People think of us as an anti-bacterial company, rather than a microbiota-manipulating company,” reflects Martin.

Advances in high-throughput screening and metagenomic data analysis have already helped uncover the microbiome’s potential as a source of new therapeutic approaches. But more new tools will be needed to further decipher the microbiome, including for instance, mathematical and computational models underpinning systems biology efforts. AvidBiotics, like other groups that have for many years been working on the microbiome, or with tools relevant to it, may have to re-position itself to benefit from the surge of interest. The company has no traditional venture capital backing, but has been supported by federal government funding, angels, and industrial conglomerate EI DuPont de Nemours & Co. Inc., which invested in 2012 to support work in food safety.

Advertisement

Related Content

Mining The Microbiome: Are Gut Microbes The Next Big Source Of Drugs?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel